earnings
confidence high
sentiment positive
materiality 0.85
GeneDx reports prelim FY2024 revenue ≥$299M (+54% YoY), above prior guidance
GeneDx Holdings Corp.
2024-FY EPS reported
-$1.94
revenue$305,450,000
- Preliminary FY2024 revenue at least $299M (+54% YoY), above prior guidance of $284-290M.
- Q4 2024 revenue at least $92M (+59% YoY, +20% sequential); exome/genome rev $75.8M (+93% YoY).
- Adjusted gross margin ≥64% FY (guidance ≥62%) and ≥68% in Q4 (up from 64% Q3).
- Q4 exome/genome volume 20,676 (+32% YoY, +7% seq); expects second consecutive adjusted net income quarter and first positive operating cash flow.
- Includes $6.8M discrete benefit from multi-year appeal recovery from a single payer.